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Asthma and risk of myelodysplastic
syndromes: a population-based cohort study
Henrik Frederiksen*,1,2, Do´ra Ko¨rmendine´ Farkas2, Erzse´bet Horva´th-Puho´2, Jan M Nørgaard3,
Mette Nørgaard2 and Henrik T Sørensen2
1Department of Haematology, Odense University Hospital, Odense, Denmark; 2Department of Clinical Epidemiology, Aarhus
University Hospital, Aarhus, Denmark and 3Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
Background: Risk factors for the development of myelodysplastic syndromes (MDS) include age, exposure to ionising radiation,
and cytotoxic drug treatment. Recently, asthma also has been suggested as a risk factor for MDS.
Methods: We undertook this nationwide population-based cohort study on patients with a first-time hospital-based asthma
diagnosis during 2002–2013 and followed them for the development of MDS/chronic myelomonocytic leukaemia (CMML).
Results: We identified 75 995 patients with incident asthma and no previous MDS/CMML diagnosis. Seventy-eight patients
subsequently developed MDS and nine patients developed CMML during 402 892 person-years. The cumulative risks of
developing MDS/CMML among asthma patients were 0.02% (95% CI: 0.01–0.04%) and 0.07% (95% CI: 0.05–0.09%) during the first
year and the first five years of follow-up, respectively. The standardised incidence ratio of MDS/CMML among asthma patients
overall was 1.6 (95% CI: 1.3–2.0) with little variation across subgroups.
Conclusions: Asthma may be a risk factor for the development of MDS/CMML.
Myelodysplastic syndromes (MDS) constitute a group of related
clonal hematopoietic disorders (Swerdlow et al, 2008). Risk factors
for MDS include age, ionising radiation, smoking, occupational
exposures, and cytotoxic drugs (Nisse et al, 1995; Andersen et al,
1998; Bjork et al, 2000; Dalamaga et al, 2002; Smith et al, 2003).
In a cohort of 22 601 women aged 55–59, self-reported asthma
in 1997 was associated with a two-fold higher risk of MDS during
the median follow-up of 14.8 years (RR¼ 2.0 (95% confidence
interval (CI): 1.0–4.6)). Outcomes were MDS and other incident
haematological malignancies identified in the State Health Registry
of Iowa (Linabery et al, 2014). Although the underlying
mechanism is unknown, immune dysregulation in MDS is evident,
as some subtypes respond to the treatment with immunosuppres-
sive or immunomodulatory agents (Saunthararajah et al, 2003; List
et al, 2005; Mollgard et al, 2011; Duong et al, 2012). Some MDS
patients also exhibit immune-mediated conditions such as
vasculitis (Farah et al, 2010). We investigated the association
between asthma and MDS/chronic myelomonocytic leukaemia
(CMML) in a large cohort of adults.
MATERIALS AND METHODS
We conducted this cohort study using the Danish National Patient
Registry (DNPR) and the Civil Registration System (CRS; Schmidt
et al, 2014; Schmidt et al, 2015). The DNPR contains information
on all inpatient discharges from hospitals since 1977, and on
outpatient clinic and emergency department visits since 1995. The
DNPR records patients’ civil registration numbers, dates of
outpatient visits, hospitalisations, and up to 20 diagnoses coded
by physicians according to the WHO’s International Classification
of Diseases, Eighth Revision (ICD-8) until 1993 and Tenth Revision
(ICD-10) thereafter. We identified all patients agedX18 years with
a first-time hospital-based diagnosis of asthma (ICD-10 codes J45–46)
in the DNPR during 2002–2013 (Byrjalsen et al, 2014) and
subsequent diagnoses of MDS or CMML (MDS code: D46, CMML
code: C93). We excluded patients whose MDS/CMML diagnosis
preceded their asthma diagnosis. The CRS has recorded date of
birth, sex, and vital status of all Danish residents since 1968.
Follow-up for MDS/CMML began on the date of the asthma
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diagnosis and continued until death, emigration, or 30 November
2013, whichever came first. Inclusion of cohort members began in
2002 after introduction of the WHO classification of MDS and
CMML (Swerdlow et al, 2008; Dinmohamed et al, 2014).
We calculated the risk of MDS/CMML after an asthma
diagnosis, treating death as a competing risk. For each calendar
year, expected numbers of MDS/CMML in the DNPR were
calculated by multiplying the person-years of observation by the
appropriate nationwide age-specific and gender-specific incidence
rates, with 5-year age groups. Standardised incidence ratios (SIRs)
– the ratio of observed numbers of incident cancers to those
expected – were used as measures of the relative risk.
We computed 95% CIs for the SIRs based on the assumption
that the observed number of cases followed a Poisson distribution.
Exact 95% CIs were used when the observed number of MDS/
CMML cases was o10; otherwise Byar’s approximation was used.
RESULTS
We identified 75 995 patients with incident asthma and no
previous diagnosis of MDS or CMML. Their median age was
48.9 years and median follow-up time was 5.0 years (IQR: 2.2–8.2
years). Seventy-eight patients developed MDS and nine patients
developed CMML during 402 892 person-years of follow-up.
During 1, 5, and 10 years of follow-up, the cumulative risks of
developing MDS/CMML for asthma patients were 0.02% (95% CI:
0.01–0.04%), 0.07% (95% CI: 0.05–0.09%), and 0.12% (95% CI:
0.09–0.15%), respectively.
Asthma patients were at increased risk of developing MDS/
CMML (SIR 1.6 (95% CI: 1.3–2.0); Table 1). SIR estimates across
subgroups were similar (Table 1). When MDS and CMML patients
were analysed separately, the SIR for MDS was identical to the
overall SIR (1.6 (95% CI: 1.3–2.0)), whereas the SIR for CMML was
imprecise (1.4 (95% CI: 0.6–2.6)) due to low numbers. The
association was observed in all subgroups, as well as among
patients without concurrent COPD (Table 1). As cancer treatment
is a risk factor for MDS, we repeated our analyses excluding asthma
patients with a previous cancer diagnosis, censoring follow-up if
patients developed a cancer diagnosis before MDS/CMML, and also
treating both the cancer and death as competing risks. These analyses
resulted in virtually identical SIR estimates (data not shown).
DISCUSSION
We found an increased risk of MDS/CMML among patients with
an asthma diagnosis. These findings are in line with the study by
Linabery et al (2014). They reported no association between
allergic diseases other than asthma and haematological malig-
nancies. In a review of the previous studies, providing estimates of
the association between allergic conditions and haematological
myeloid neoplasms, Wang and Diepgen (2005) reported imprecise
risk estimates around unity. In a case–control study that
specifically included MDS patients and examined self-reported
allergic conditions other than asthma, no differences in frequencies
of allergies were observed between the MDS patients and their
controls (Pekmezovic et al, 2006).
The mechanism linking asthma to MDS/CMML remains
unknown. Although, epigenetic modifications are common to
MDS/CMML and asthma (Yang and Schwartz, 2012; Bravo et al,
2014), they are unlikely to explain the association as the hallmark
of MDS/CMML is clonal proliferation of neoplastic cells with
subsequent epigenetic modifications, whereas asthma is a non-
clonal disease.
Most previous studies of allergic conditions and risk of
haematological cancers have focused on lymphoid malignancies
(Wang and Diepgen, 2005; Turner et al, 2006; Melbye et al, 2007),
with conflicting results. Some studies have found that allergic
conditions and specific IgE titres were associated with the
decreased risk of lymphoid haematological malignancies, (Wang
and Diepgen, 2005), but one study suggested that these findings
may be attributed to reverse causality, that is, immunological
Table 1. Observed and expected numbers of patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic
leukemia (CMML), and standardised incidence ratios (SIRs), among Danish patients diagnosed with asthma during 2002–2013
and followed for MDS and CMML
Patient characteristics (n)
Person-years of follow-up
among patients with asthma
Asthma patients with
MDS or CMML (n)
Expected MDS/CMML
cases (n) SIR (95% CI)
All (75 995) 402 892 87 54.6 1.6 (1.3–2.0)
Women (47 385) 249 358 47 26.5 1.8 (1.3–2.4)
Men (28 610) 153 533 40 28.1 1.4 (1.0–1.9)
Age at asthma diagnosis (years)
18–44 (32 712) 192 487 6 2.7 2.2 (0.8–4.9)
45–70 (31 187) 165 779 41 24.2 1.7 (1.2–2.3)
71þ (12 096) 44 626 40 27.7 1.4 (1.0–2.0)
Year of asthma diagnosis
2002–2007 (38 413) 300 173 60 36.0 1.7 (1.3–2.2)
2008–2013 (37 582) 102 719 27 18.6 1.5 (1.0–2.1)
Follow-up time
0–1 yr (75 995) 70 645 21 7.7 2.7 (1.7–4.2)
2–5 yrs (66 393) 205 764 35 24.2 1.5 (1.0–2.0)
6–10 yrs (37 644) 116 848 24 19.1 1.3 (0.8–1.9)
410 yrs (9921) 9634 7 3.6 1.9 (0.8–4.0)
Hospital contact type
Inpatient admission (26 170) 131 407 41 22.6 1.8 (1.3–2.5)
Outpatient specialist clinic visit only (42 497) 229 960 35 27.4 1.3 (0.9–1.8)
Emergency room only (7328) 41 525 11 4.6 2.4 (1.2–4.3)
Presence of chronic obstructive pulmonary
disease (COPD)
Asthma and COPD (10 829) 44 941 28 13.9 2.0 (1.3–2.9)
Asthma without COPD (65 166) 357 950 59 40.7 1.5 (1.1–1.9)
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response to IgE-specific allergens may be compromised among
patients with the developing lymphomas (Melbye et al, 2007).
Despite its large size, and complete follow-up, our study has
limitations. We included only asthma diagnosed in hospital-based
settings. Some asthma patients may be diagnosed and followed by
their general practitioner without a hospital contact (Hanania et al,
2011). However, asthma patients above 65 years of age (B10% of
prevalent asthma cases) are most likely to be referred to hospital-
based care (Hanania et al, 2011). As the incidence of MDS/CMML
increases with age, (Dinmohamed et al, 2014) a larger proportion
of MDS/CMML patients with a preceding asthma diagnosis would
have had a hospital-based asthma diagnosis. During the first year
following asthma diagnosis, the SIR estimate for MDS/CMML
development was higher than in the following years. Heightened
diagnostic effort probably explains part of the association in the
short term. However, the increased risk was remarkably persistent
many years after an asthma diagnosis.
In the DNPR, the completeness of the asthma diagnosis in
conscripts has been found to be 0.44 and the specificity to be 0.98
(Jensen et al, 2010). Asthma patients with a hospital referral,
however could have a higher risk of MDS/CMML than asthma
patients treated only by general practitioners due to potentially,
more severe asthma and higher levels of comorbidity. As well,
because of our study’s registry-based design, we lacked detailed
patient-specific information, such as smoking status. Still, when we
used a concurrent COPD diagnosis as a proxy for smoking, we
observed the association between asthma and MDS/CMML among
the asthma patients without COPD.
We conclude that asthma may be a risk factor for the
development of MDS/CMML.
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